FOSAMAX TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

ALENDRONIC ACID (ALENDRONATE SODIUM)

Disponible des:

MERCK CANADA INC

Codi ATC:

M05BA04

Designació comuna internacional (DCI):

ALENDRONIC ACID

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

ALENDRONIC ACID (ALENDRONATE SODIUM) 10MG

Vía de administración:

ORAL

Unidades en paquete:

28

tipo de receta:

Prescription

Área terapéutica:

BONE RESORPTION INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0150323003; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2011-11-10

Fitxa tècnica

_ _
_Product Monograph – FOSAMAX_
_®_
_ _
_Page 1 of 50_
PRODUCT MONOGRAPH
FOSAMAX
®
alendronate sodium tablets
5 MG, 10 MG, 40 MG AND 70 MG ALENDRONATE
alendronate sodium oral solution
70 MG/75 ML ALENDRONATE
Bone Metabolism Regulator
MERCK FROSST CANADA LTD.
16711 Trans Canada Highway
Kirkland QC H9H 3L1
Canada
www.merckfrosst.com
DATE OF REVISION:
SEPTEMBER 10, 2010
SUBMISSION CONTROL NO: 139605
FOSAMAX
®
is a Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary
of
MERCK & CO., INC.
Used
under license.
_ _
_Product Monograph – FOSAMAX_
_®_
_ _
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................7
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND
STABILITY..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL
INFORMATION